Label Changes for:
Vimpat (Lacosamide) Tablets, Injection and Oral Solution
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2013
- Blood and lymphatic system disorders: Agranulocytosis